Phase 3 randomized placebo-controlled study of rozanolixizumab in adults with relapsing MOG antibody-associated disease

Phase 3, randomised, double-blind trial of rozanolixizumab in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (3 arms), sponsored by UCB. Primary endpoints: Time from randomization to first independently centrally adjudicated relapse, Incidence of treatment-emergent adverse events and 1 more. Planned start Aug 2022; status: authorised.